Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News TVT 2023

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

Shelley Wood

June 14, 2023

News Features TVT 2022

Minorities, Poorer Patients Missing Out on Structural Heart Care

Michael O'Riordan

June 15, 2022

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

News Conference News TVT 2021

3M TAVR: Minimalist TAVI Pathway Saves Money

Todd Neale

July 26, 2021

News Conference News TVT 2019

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Shelley Wood

June 14, 2019

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

Presentation TVT 2014

A Citizen of the World and Frequent TAVR Proctor

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

An Interventionalist from London, UK

Presenter: Martyn R. Thomas

June 07, 2014

Presentation TVT 2014

A Surgeon from Dallas, Texas

Presenter: Michael J. Mack

June 07, 2014

Presentation TVT 2014

The Daunting Task of Explaining High TAVR Costs to Practitioners, Hospital Administrators, and Healthcare Systems

Presenter: Larry L. Wood

June 07, 2014

Presentation TVT 2014

Are Reimbursement Patterns Directly Affecting TAVR Clinical Usage in Europe?

Presenter: Nicolo Piazza

June 07, 2014

Presentation TVT 2014

TAVR is not Cost Effective Compared with Surgery (in Most Patients)!

Presenter: A. Pieter Kappetein

June 07, 2014

Presentation TVT 2014

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Presenter: David J. Cohen

June 07, 2014

Advertisement

Five-Year Follow-up Reassures on Severe Patient-Prosthesis Mismatch in TAVI

Minorities, Poorer Patients Missing Out on Structural Heart Care

More Support for Single Antiplatelet Therapy After TAVI

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

3M TAVR: Minimalist TAVI Pathway Saves Money

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

A Citizen of the World and Frequent TAVR Proctor

An Interventionalist from London, UK

A Surgeon from Dallas, Texas

The Daunting Task of Explaining High TAVR Costs to Practitioners, Hospital Administrators, and Healthcare Systems

Are Reimbursement Patterns Directly Affecting TAVR Clinical Usage in Europe?

TAVR is not Cost Effective Compared with Surgery (in Most Patients)!

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content